Gland Pharma Limited announced strong financial performance for the quarter and year ended March 31, 2026. The company achieved a 22% year-on-year revenue increase in Q4 FY26 and a 14.5% revenue growth for the full financial year. Driven by growth in its CDMO segment, base business momentum, and successful product launches, the board has recommended a final dividend of ₹20 per equity share, payable following the 48th Annual General Meeting.
Financial Highlights for FY26
Gland Pharma demonstrated robust growth throughout the fiscal year. The company reported annual revenue from operations of ₹64,307 million, representing a 14% increase over the previous year. Adjusted EBITDA for the year stood at ₹16,826 million, marking a 33% growth. Similarly, Adjusted PAT reached ₹10,455 million, a 50% improvement compared to the previous fiscal year.
Quarterly Performance Review
For the fourth quarter ended March 31, 2026, the company recorded revenue from operations of ₹17,428 million, a 22% growth compared to the same quarter last year. Adjusted PAT for the quarter surged by 97% year-on-year to ₹3,667 million. This strong quarterly performance was supported by significant contributions from the CDMO segment, which grew 36% year-on-year during this period.
Strategic Business Updates
During FY26, the company launched 31 products in the USA. Significant operational milestones include the filing of 24 ANDAs and the approval of 28 ANDAs throughout the year. The company’s R&D investment totaled ₹2,230 million for FY26, focusing heavily on complex product development. Additionally, the company secured a new Nano Drug Delivery System-based oncology contract as part of its expanding CDMO portfolio.
Dividend and AGM Information
The Board of Directors has recommended a final dividend of ₹20 per equity share (face value of ₹1 each) for the financial year 2025-26. The record date to determine member eligibility for this dividend is Tuesday, August 11, 2026. The 48th Annual General Meeting is scheduled to be held on Tuesday, August 25, 2026, via video conferencing.
Source: BSE
